{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T03:41:48Z","timestamp":1772854908446,"version":"3.50.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T00:00:00Z","timestamp":1705536000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T00:00:00Z","timestamp":1705536000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["115523"],"award-info":[{"award-number":["115523"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Invasive <jats:italic>Escherichia coli<\/jats:italic> disease (IED) encompasses a diverse range of sterile site infections. This study evaluated the feasibility of capturing IED among community-dwelling older adults to inform the implementation of a phase 3 efficacy trial of a novel vaccine against IED (NCT04899336).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>EXPECT-1 (NCT04087681) was a prospective, multinational, observational study conducted in medically stable participants aged\u2009\u2265\u200960\u00a0years. At least 50% of participants were selected based on a history of urinary tract infection (UTI) in the previous 10\u00a0years. The main outcomes were the incidence of IED and the number of hospitalisations reported by the site vs participant. The length of follow-up was 12\u00a0months. In a US-based substudy, a smartphone-based geofencing was evaluated to track hospital entries.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In total, 4470 participants were enrolled (median age, 70.0\u00a0years); 59.5% (2657\/4469) of participants had a history of UTI in the previous 10\u00a0years. Four IED events were captured through deployment of different tracking methods: a self-report, a general practitioner (GP) report, and a follow-up call. The incidence rate of IED was 98.6 events per 100,000 person-years. The number of reported hospitalisations was 2529\/4470 (56.6%) by the site and 2177\/4470 (48.7%) by participants; 13.8% of hospitalisations would have been missed if utilising only site reports. Geofencing detected 72 hospital entries.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Deployment of multiple tracking methods can optimise detection of IED among community-dwelling older adults. Older adults with a history of UTI could be feasibly targeted for a phase 3 vaccine efficacy trial through a network of GPs.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10096-023-04738-y","type":"journal-article","created":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T11:43:09Z","timestamp":1705578189000},"page":"541-550","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Feasibility of tracking invasive Escherichia coli disease among older adults in a community setting: A prospective observational study"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3503-3596","authenticated-orcid":false,"given":"Joachim","family":"Doua","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5475-7875","authenticated-orcid":false,"given":"Miquel","family":"Ekkelenkamp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0166-1498","authenticated-orcid":false,"given":"Theo","family":"Verheij","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oscar","family":"Go","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9682-3826","authenticated-orcid":false,"given":"Stephen","family":"Ruhmel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly","family":"Leathers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bart","family":"Spiessens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanne","family":"van Rooij","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"Vance G.","family":"Fowler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeroen","family":"Geurtsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7317-9468","authenticated-orcid":false,"given":"Rowena","family":"Dolor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7035-0020","authenticated-orcid":false,"given":"Michal","family":"Sarnecki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4294-8081","authenticated-orcid":false,"given":"Ranee","family":"Chatterjee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9583-8126","authenticated-orcid":false,"given":"Jan","family":"Poolman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Bonten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf COMBACTE-NET consortium\/EXPECT study group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,1,18]]},"reference":[{"key":"4738_CR1","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1093\/femsre\/fuw005","volume":"40","author":"J Vila","year":"2016","unstructured":"Vila J, S\u00e1ez-L\u00f3pez E, Johnson JR, R\u00f6mling U, Dobrindt U, Cant\u00f3n R, Giske CG, Naas T, Carattoli A, Mart\u00ednez-Medina M, Bosch J, Retamar P, Rodr\u00edguez-Ba\u00f1o J, Baquero F, Soto SM (2016) Escherichia coli: an old friend with new tidings. FEMS Microbiol Rev 40:437\u2013463. https:\/\/doi.org\/10.1093\/femsre\/fuw005","journal-title":"FEMS Microbiol Rev"},{"key":"4738_CR2","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1128\/cmr.00002-14","volume":"27","author":"KB Laupland","year":"2014","unstructured":"Laupland KB, Church DL (2014) Population-based epidemiology and microbiology of community-onset bloodstream infections. Clin Microbiol Rev 27:647\u2013664. https:\/\/doi.org\/10.1128\/cmr.00002-14","journal-title":"Clin Microbiol Rev"},{"key":"4738_CR3","doi-asserted-by":"publisher","first-page":"e202899","DOI":"10.1001\/jamanetworkopen.2020.2899","volume":"3","author":"C Rhee","year":"2020","unstructured":"Rhee C, Kadri SS, Dekker JP, Danner RL, Chen HC, Fram D, Zhang F, Wang R, Klompas M (2020) Prevalence of antibiotic-resistant pathogens in culture-proven sepsis and outcomes associated with inadequate and broad-spectrum empiric antibiotic use. JAMA Netw Open 3:e202899. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.2899","journal-title":"JAMA Netw Open"},{"key":"4738_CR4","doi-asserted-by":"publisher","first-page":"e206004","DOI":"10.1001\/jamanetworkopen.2020.6004","volume":"3","author":"K Fay","year":"2020","unstructured":"Fay K, Sapiano MRP, Gokhale R, Dantes R, Thompson N, Katz DE, Ray SM, Wilson LE, Perlmutter R, Nadle J, Godine D, Frank L, Brousseau G, Johnston H, Bamberg W, Dumyati G, Nelson D, Lynfield R, DeSilva M, Kainer M, Zhang A, Ocampo V, Samper M, Pierce R, Irizarry L, Sievers M, Maloney M, Fiore A, Magill SS, Epstein L (2020) Assessment of health care exposures and outcomes in adult patients with sepsis and septic shock. JAMA Netw Open 3:e206004. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.6004","journal-title":"JAMA Netw Open"},{"key":"4738_CR5","doi-asserted-by":"publisher","unstructured":"Geurtsen J, de Been M, Weerdenburg E, Zomer A, McNally A, Poolman J (2022) Genomics and pathotypes of the many faces of Escherichia coli. FEMS Microbiol Rev 46(6):fuac031. https:\/\/doi.org\/10.1093\/femsre\/fuac031","DOI":"10.1093\/femsre\/fuac031"},{"key":"4738_CR6","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/s0140-6736(21)02724-0","volume":"399","author":"Antimicrobial Resistance Collaborators","year":"2022","unstructured":"Antimicrobial Resistance Collaborators (2022) Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet 399:629\u2013655. https:\/\/doi.org\/10.1016\/s0140-6736(21)02724-0","journal-title":"Lancet"},{"key":"4738_CR7","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1093\/cid\/ciaa210","volume":"72","author":"M Bonten","year":"2021","unstructured":"Bonten M, Johnson JR, van den Biggelaar AHJ, Georgalis L, Geurtsen J, de Palacios PI, Gravenstein S, Verstraeten T, Hermans P, Poolman JT (2021) Epidemiology of Escherichia coli bacteremia: A systematic literature review. Clin Infect Dis 72:1211\u20131219. https:\/\/doi.org\/10.1093\/cid\/ciaa210","journal-title":"Clin Infect Dis"},{"key":"4738_CR8","doi-asserted-by":"publisher","unstructured":"Bou-Antoun S, Davies J, Guy R, Johnson AP, Sheridan EA, Hope RJ (2016) Descriptive epidemiology of Escherichia coli bacteraemia in England, April 2012 to March 2014. Euro Surveill 21(35):pii=30329. https:\/\/doi.org\/10.2807\/1560-7917.Es.2016.21.35.30329","DOI":"10.2807\/1560-7917.Es.2016.21.35.30329"},{"key":"4738_CR9","unstructured":"A study of vaccination with 9-valent extraintestinal pathogenic Escherichia coli vaccine (ExPEC9V) in the prevention of invasive extraintestinal pathogenic Escherichia coli disease in adults aged 60 years and older with a history of urinary tract infection in the past 2 years. NCT04899336. https:\/\/clinicaltrials.gov\/study\/NCT04899336. Accessed 17 Jan 2024"},{"key":"4738_CR10","doi-asserted-by":"publisher","first-page":"23","DOI":"10.5492\/wjccm.v1.i1.23","volume":"1","author":"P Nasa","year":"2012","unstructured":"Nasa P, Juneja D, Singh O (2012) Severe sepsis and septic shock in the elderly: an overview. World J Crit Care Med 1:23\u201330. https:\/\/doi.org\/10.5492\/wjccm.v1.i1.23","journal-title":"World J Crit Care Med"},{"key":"4738_CR11","doi-asserted-by":"publisher","unstructured":"Nguyen KT, Olgin JE, Pletcher MJ, Ng M, Kaye L, Moturu S, Gladstone RA, Malladi C, Fann AH, Maguire C, Bettencourt L, Christensen MA, Marcus GM (2017) Smartphone-based geofencing to ascertain hospitalizations. Circ Cardiovasc Qual Outcomes 10(3):e003326. https:\/\/doi.org\/10.1161\/circoutcomes.116.003326","DOI":"10.1161\/circoutcomes.116.003326"},{"key":"4738_CR12","unstructured":"COMBACTE-NET (2022) Combatting bacterial resistance in Europe-Networks https:\/\/www.combacte.com\/about\/about-combacte-net-detail\/. Accessed 23 March 2022"},{"key":"4738_CR13","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.jhin.2016.12.008","volume":"95","author":"J Abernethy","year":"2017","unstructured":"Abernethy J, Guy R, Sheridan EA, Hopkins S, Kiernan M, Wilcox MH, Johnson AP, Hope R (2017) Epidemiology of Escherichia coli bacteraemia in England: results of an enhanced sentinel surveillance programme. J Hosp Infect 95:365\u2013375. https:\/\/doi.org\/10.1016\/j.jhin.2016.12.008","journal-title":"J Hosp Infect"},{"key":"4738_CR14","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.jhin.2019.05.007","volume":"103","author":"PJ Lillie","year":"2019","unstructured":"Lillie PJ, Johnson G, Ivan M, Barlow GD, Moss PJ (2019) Escherichia coli bloodstream infection outcomes and preventability: a six-month prospective observational study. J Hosp Infect 103:128\u2013133. https:\/\/doi.org\/10.1016\/j.jhin.2019.05.007","journal-title":"J Hosp Infect"},{"key":"4738_CR15","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/nrmicro3432","volume":"13","author":"AL Flores-Mireles","year":"2015","unstructured":"Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ (2015) Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol 13:269\u2013284. https:\/\/doi.org\/10.1038\/nrmicro3432","journal-title":"Nat Rev Microbiol"},{"key":"4738_CR16","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1007\/s15010-007-6180-2","volume":"35","author":"KB Laupland","year":"2007","unstructured":"Laupland KB, Ross T, Pitout JD, Church DL, Gregson DB (2007) Community-onset urinary tract infections: a population-based assessment. Infection 35:150\u2013153. https:\/\/doi.org\/10.1007\/s15010-007-6180-2","journal-title":"Infection"}],"container-title":["European Journal of Clinical Microbiology &amp; Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-023-04738-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10096-023-04738-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-023-04738-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T14:12:38Z","timestamp":1709734358000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10096-023-04738-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,18]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["4738"],"URL":"https:\/\/doi.org\/10.1007\/s10096-023-04738-y","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,18]]},"assertion":[{"value":"19 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and that are consistent with Good Clinical Practices and applicable regulatory requirements. The protocol, Informed Consent Form, and other relevant documents were submitted to an Institutional Review Board\/Independent Ethics Committee (IRB\/IEC) by the investigator and reviewed and approved by the IRB\/IEC before the study was initiated.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Participants or their legally acceptable representatives provided their written consent to participate in the study after having been informed about the nature and purpose of the study and participation\/termination conditions. Informed consent was obtained before enrollment into the study on the first visit. Personal data from participants enrolled in this study (limited to those data necessary to address the objectives of the study) were collected and processed with adequate precautions to ensure confidentiality and compliance with applicable data privacy protection laws and regulations. A copy of the ICF(s) was provided to the participant or the participant\u2019s legally authorized representative.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Joachim Doua is an employee of Janssen Research & Development (a pharmaceutical company of Johnson & Johnson). Miquel Ekkelenkamp discloses that this project was funded by Innovative Medicines Initiative (IMI) of European Commission (hours declared on this project), COMBACTE-NET (grant agreement number 115523). Theo Verheij has no conflicts of interest to disclose. Oscar Go is an employee of Janssen Research & Development and owns equities. Stephen Ruhmel is an employee of Janssen Research & Development and owns stock and options in Johnson & Johnson. Kimberly Leathers has no conflicts of interest to disclose. Bart Spiessens was an employee of Janssen (a pharmaceutical company of Johnson & Johnson) at the time of the study and owns shares in Janssen. Sanne van Rooij has no conflicts of interest to disclose. Vance G. Fowler Jr discloses support for the present manuscript from the NIH; grants or contracts to his affiliated institution from the NIH, MedImmune, Allergan, Pfizer, Advanced Liquid Logics, Theravance, Novartis, Merck, Medical Biosurfaces, Locus, Affinergy, Contrafect, Karius, Genentech, Regeneron, Basilea, Janssen; royalties and licences from UpToDate; consulting fees from Novartis, Debiopharm, Genentech, Achaogen, Affinium, Medicines Co., MedImmune, Bayer, Basilea, Affinergy, Janssen, Contrafect, Regeneron, Destiny, Amphliphi Biosciences, Integrated Biotherapeutics, C3J, Armata, Valanbio, Akagera, Aridis, Roche, Pfizer; support by Contrafect for presenting phase 2 data at ECCMID 2019; a sepsis diagnostics patent; a role as an associate editor for <i>Clinical Infectious Diseases<\/i> between 2017\u20132022; and stock\/stock options in ArcBio and ValanBio. Jeroen Geurtsen is an employee of Janssen Vaccines & Prevention (a pharmaceutical company of Johnson & Johnson) and owns stock options in Johnson & Johnson. Rowena Dolor discloses payments made to Duke University for this research project and a relationship with Universitair Medisch Centrum Utrecht. Michal Sarnecki is an employee of Janssen Vaccines, Branch of Cilag GmbH International Pharmaceutical (a pharmaceutical company of Johnson & Johnson) and owns unrestricted shares in Janssen Vaccines. Ranee Chatterjee has no conflicts of interest to disclose. Jan Poolman is an employee of Janssen Research & Development and owns stock options in Janssen Research & Development. Marc Bonten discloses grants or contracts paid to the University Medical Centre Utrecht (UMCU) by Janssen Vaccines, Novartis, CureVac and Merck; payment or honoraria to MJMB from Takeda; and payments to UMCU for participation on a data safety monitoring board or advisory board from Sanofi, Spherecydes, Pfizer, Merck, Novartis, and AstraZeneca.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}